estimate costs for in-and outpatients. RESULTS: Among the 264_PAND and 132_POST inpatients, 30% were Ͻ18 years old, and 45% were women. The mean length of stay at general ward was of 6.5(6.1)-7.0(6.6) days (PAND and POST, respectively); and between 8.2(5.0) and 11.5(15.2) days for ICU patients (7%_PAND and 20%_POST). Among employed (45.3% PAND and 37.7% POST) most went on sick leave (99% and 93%) for about 31(37) and 38(27) days. Among outpatients (215_PAND and 175_POST), about 25-35% were under 17 years old, and 50-57% were women. The 94%(PAND) and 82%(POST) of employed (64,9% and 68,0%, respectively) went on sick leave. Absenteeism length of was 11(12)-7(45) days. The mean cost per inpatient was 6,028 € (SDϭ6,251) in PAND and 6,939€(SDϭ10,895) in POST. For outpatients the mean cost was 749€ (SDϭ886) in PAND and 421€ (SDϭ686) in POST. CONCLUSIONS: Contrary to what expected, resource utilization was quite similar for both influenza waves. However, differences on mean cost were found due to the slightly increase in inpatients health care utilization, and the decrease of absenteeism among outpatients during the post-pandemic wave. These results would be useful to assess the influenza real burden in Spain; both at individual and population level. After adjusting for all baseline differences, cases on an average had $912 (95% CL:$781-$1,042) greater overall cost per subject compared to controls. Top three drivers were attributed to outpatient costs (58%, $533), inpatient costs (22%, $201), and pharmacy costs (15%, $139), respectively. Among cases, dermatology-related overall costs were 370% (from $127 to $470) greater post index event. Over 80% of this increase was attributable to dermatology-related outpatient costs. Approximately, three additional dermatology-related outpatient visits were observed in the follow-up period compared to baseline. CONCLUSIONS: AD is costing the U.S. payer an additional $912 per-patient-per-year compared to subjects with no AD. Future research should determine the impact of current treatment on the economic burden of this disease. 
PHS19

MACRO-COSTING ANALYSIS OF HOSPITAL STAY IN HEART FAILURE PATIENTS IN TURKISH SETTING
Atatürk Training and Research Hospital, Izmir, Turkey, 2 Servier Ilac ve Arastirma A.S., Istanbul, Turkey, 3 Yorum Consulting Co. Ltd., Istanbul, Turkey OBJECTIVES: The economic burden of heart failure (HF) has increased rapidly with the increasing prevalence and incidence of HF patients all around the world. In this abstract, the cost analysis of hospitalized HF patients is presented. METHODS: A sample of hospitalizations (nϭ166, year 2011) with diagnoses related with chronic HF in a state hospital serving to a wide range of populations was evaluated. The prices for ICU stay and cardiovascular procedures paid by Turkish state health security system were applied. Indirect costs are not taken into account. RESULTS: Twelve percent of the stays were in intensive care unit (ICU), 35% were in medical ward only and 53% of the stays were partly in ICU and medical ward; average duration were 2.51Ϯ3.09 days, 4.45Ϯ4.07 days and 6.95Ϯ5.08 days, respectively. ICU stays are paid with fixed prices, without allowance for any extra payment for services or procedures performed while the patient stays in ICU. Average daily and total costs of ICU stay are calculated as 402€/day and 1006€, respectively. On the other hand, procedures are paid per service, while the patient stays in medical ward. Therefore the fixed amounts of payments for cardiovascular procedures, which are mostly performed during the stay of HF patients, were averaged by the frequencies of individual procedures. This yielded to 531€ per stay. Therefore the total cost of stay was obtained as 1537€, and average daily cost of stay as 221€/day. CONCLUSIONS: These figures are quite concordant with a previous analysis reported in 2009 (total cost of stay 1617€ and daily cost of stay 245€/day) in which micro-costing methods had been applied. Therefore these figures presented in this report could be used local input parameters for health economics models for HF.
PHS20 COST ASSOCIATED TO THE MANAGEMENT OF INAPPROPRIATE SHOCKS IN PATIENTS WITH AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR -CARDINA STUDY
Pereferrer D OBJECTIVES: Inappropriate shocks are the most common complications of ICD, causing a negative effect on patients' morbidity and mortality. Little is known with regards to the cost associated to the management of IS. The aim of the study was to determine IS related factors and to evaluate its associated hospital cost. METHODS: All patients implanted with an ICD where retrospectively analyzed through clinical chart reviews in a Spanish hospital from 2003 to 2011. Demographic variables, baseline cardiomyopathy, comorbidities, indication and type of ICD implanted were registered. During the follow up period we identified the presence of IS, its reasons and associated costs. RESULTS: A total of 227 patients were implanted with an ICD, mean age 63.2 years (26-82). Eighty-six percent were men, 64.6% with ischemic cardiomyopathy, 78.4% with heart failure, 70.4% with EFϽ35% and 13.1% with AF. The proportion of single, dual and three chambers ICD was 54.6%, 20.3% and 25.1% respectively. After a median follow up of 4.46 years, 27 patients had had 42 IS episodes. Average time since implant to first IS was 1.3 years (range 0.02 to 3.84 years). Patients suffering from IS had higher mortality (33.3% vs 13.7%; pϽ0.05). Amost 67% of the episodes were due to supraventricular tachycardia, 12% to noise detection, 19% to Wave T overdetection and 2.3% due to other causes. Sixty-three percentages of the episodes generated an emergency visit and a 39% generated a non-scheduled visit to the cardiologist. Seven episodes (16.7%) required hospitalization, six of whom required a surgical intervention. Average length of stay was 5.1 days. Finally, overall mean hospital cost appeared to be €5,175 per episode. CONCLUSIONS: The cost of inappropriate shocks is driven by the reason of its cause. The great majorities of the episodes were due to supraventricular arrhythmias and finally resolved without the need for hospitalization. ). The majority of out-of-pocket expenses for AF were non-medical costs for treatment and services not covered by insurance, including travel and household help. The proportion of patients who claimed cost as a reason for not filling a prescription or skipping doses ranged from 3% in the UK and Spain to 10% in France. Failure to receive treatment due to lack of reimbursement was experienced least frequently in the UK (1% of patients) and most frequently in Germany (28% of patients). CONCLUSIONS: The EUPS-AF highlights differences in out-of-pocket expenses and levels of treatment reimbursement that patients with AF have to pay in five European countries. Payers, health care policy makers and clinicians should all be aware that the financial burden of AF is linked to treatment adherence and may affect patient satisfaction and treatment outcome. CR, SK) and insurance records (HU). Direct costs from the payer's perspective were based on published national sources (CR, SK), DRG lists (PL) and the insurance records (HU). RESULTS: The incidence of hospitalized bacteraemia/sepsis and meningitis per 100,000 person years were: 2.07 and 1.34 (CR), 1.2 and 0.49 (SK), 0.66 and 0.32 (PL), and 3.16 and 1.01 (HU). The case fatality rate was: 31% and 25%, 12% and 25%, 40% and 63%, and 11% and 29%. An exponential increase in both measures was apparent with advancing age. The total economic burden of IPD in adults over 50 was : EUR 666, 050; 159, 528; 180, 015 and 140, 249 . Adults Ն65, who represent 41% of the combined population, account for 54% of the costs. CONCLUSIONS: The IPD burden in adults increases with age, and is associated with a high risk of death. Higher incidence in HU obtained from insurance records seems to more reliably reflect the reality and highlights systematic underreporting of national surveillance systems. 
PHS21 OUT-OF-POCKET FINANCIAL BURDEN IN ATRIAL FIBRILLATION AND POTENTIAL IMPACT ON CARE: COMPARISON ACROSS FIVE EUROPEAN COUNTRIES USING THE EUROPEAN PATIENT SURVEY IN ATRIAL FIBRILLATION (EUPS-AF)
PHS22 BURDEN OF INVASIVE PNEUMOCOCCAL DISEASES IN OLDER ADULTS IN THE NEW EU COUNTRIES OF THE CENTRAL EUROPE
PHS23 DIRECT MEDICAL COSTS ASSOCIATED WITH STROKE IN NON-VALVULAR ATRIAL FIBRILLATION IN INDIA
OBJECTIVES:
To estimate the stroke related disease burden in terms of health care resource utilization and average per-patient costs among patients with a prior diagnosis of non-valvular atrial fibrillation (NVAF) in India. METHODS: Data were collected retrospectively in three large multidisciplinary community hospitals in three cities in India. Medical charts of 400 patients diagnosed with stroke and NVAF from June 1, 2011 to September 1, 2011 were reviewed. Data abstracted were demographic characteristics, clinical diagnosis, risk factors, comorbid conditions, date of diagnosis/admission, date of discharge, and types of inpatient procedures. Data regarding outpatient services such as physician visits, laboratory tests, INR monitoring, diagnostic tests, nursing services, and speech/physiotherapy over a three month period post-discharge were obtained via patient follow-up surveys. Costs associated with inpatient services were obtained from hospital discharge bills and the pricing menu of the three hospitals. RESULTS: The mean age of patients in the study was 59 (SD 10) and the majority of patients (62%) were male. Of the 400 patients, 61% had ischemic stroke and about 60% of the patients were moderate to moderate-severe disabled based on the modified Rankin Scale. The mean length of stay for patients with ischemic stroke was 16 days (SD 4). The direct medical costs for patients with moderate or more severe ischemic stroke (inpatient and outpatient) over the 3 month follow-up period was Indian rupees, Rs 130, 976 (SD 3, 913) with inpatient hospital costs accounting for a major portion (Rs 114,202) of the overall costs (per patient). CONCLUSIONS: The findings of the study indicated that the acute treatment for 3 months post ischemic stroke among NVAF patients imposes considerable economic burden (US $7,138) among patients in India. As inpatient costs are major cost drivers, clinical efforts should focus on timely management of NVAF induced strokes and use of preventive treatments. 
PHS24 COST OF TRAFFIC ACCIDENTS RELATED TO LOW VISIBILITY CONDITIONS: A COST OF ILLNESS STUDY
OBJECTIVES:
To calculate the health care cost of traffic accidents occurring in night or daylight under low visibility. METHODS: Data on traffic accidents derive from the database of Hungarian Central Statistical Office (HCSO). We assessed the cost of both health services in kind and health services in cash. The direct cost related to traffic accidents were derived from the financial database of the National Health Insurance Fund Administration, the only health care financing agency in Hungary (Hungarian DRG point system version 5.0). Cost of benefits in cash was calculated with an average sick pay. The average recovery period of patients with traffic accidents was assumed 4 months. RESULTS: A total of 20635 persons were injured and 1106 persons were died on the road by traffic accident. 45 percent of casualty has been taken in night or daylight under low visibility. Average cost of restricted visibility accidents is 510886 HUF per capita (approx. 2041 EURO). We calculated an average sick pay 119365 HUF (approx. 477 Euro) per capita per month. The expenditures of the National Health Insurance Fund Administration could easily reach the 17 billion HUF (approx. 67.9 million Euro) per years. CONCLUSIONS: Traffic accidents and subsequent medical conditions are important burden for the Hungarian health insurance system with an annual expenditure of 17 billion HUF (97,9 million EURO). Better illumination, law regulation, appropriate education and traffic instructions might decrease the costs related to accidents on the road.
